These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

689 related articles for article (PubMed ID: 31581314)

  • 1. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
    Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
    Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of metastasis in BRCA2 carriers diagnosed with triple-negative breast cancer.
    Moreno M; Oliveira JS; Brianese RC; de Castro DG; Sanches SM; Torrezan GT; Santiago KM; De Brot M; Cordeiro de Lima VC; Baroni Alves Makdissi F; Casali Da Rocha JC; Calsavara VF; Carraro DM
    Cancer Med; 2023 Aug; 12(15):16129-16141. PubMed ID: 37485802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system metastases in breast cancer patients with germline BRCA pathogenic variants compared to non-carriers: a matched-pair analysis.
    Ben-Zion Berliner M; Yust-Katz S; Lavie I; Goldberg Y; Kedar I; Yerushalmi R
    BMC Cancer; 2024 Feb; 24(1):219. PubMed ID: 38365640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
    Castro E; Goh C; Olmos D; Saunders E; Leongamornlert D; Tymrakiewicz M; Mahmud N; Dadaev T; Govindasami K; Guy M; Sawyer E; Wilkinson R; Ardern-Jones A; Ellis S; Frost D; Peock S; Evans DG; Tischkowitz M; Cole T; Davidson R; Eccles D; Brewer C; Douglas F; Porteous ME; Donaldson A; Dorkins H; Izatt L; Cook J; Hodgson S; Kennedy MJ; Side LE; Eason J; Murray A; Antoniou AC; Easton DF; Kote-Jarai Z; Eeles R
    J Clin Oncol; 2013 May; 31(14):1748-57. PubMed ID: 23569316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline mutation in DNA-repair genes is associated with poor survival in BRCA1/2-negative breast cancer patients.
    Fan Z; Hu L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    Cancer Sci; 2019 Oct; 110(10):3368-3374. PubMed ID: 31432574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China.
    Cao W; Xie Y; He Y; Li J; Wang T; Fan Z; Fan T; Ouyang T
    Breast Cancer Res Treat; 2019 Jun; 175(3):749-754. PubMed ID: 30895535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
    Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes and risk of subsequent breast events in breast-conserving surgery patients with BRCA1 and BRCA2 mutation.
    Ye F; Huang L; Lang G; Hu X; Di G; Shao Z; Cao A
    Cancer Med; 2020 Mar; 9(5):1903-1910. PubMed ID: 31912664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.
    Halpern N; Sonnenblick A; Uziely B; Divinsky L; Goldberg Y; Hamburger T; Peretz T; Kadouri L
    Int J Cancer; 2017 May; 140(9):2145-2149. PubMed ID: 28120435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
    Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
    Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
    Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
    Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.
    van den Broek AJ; Schmidt MK; van 't Veer LJ; Oldenburg HSA; Rutgers EJ; Russell NS; Smit VTHBM; Voogd AC; Koppert LB; Siesling S; Jobsen JJ; Westenend PJ; van Leeuwen FE; Tollenaar RAEM
    Ann Surg; 2019 Aug; 270(2):364-372. PubMed ID: 29727326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.
    Malone KE; Begg CB; Haile RW; Borg A; Concannon P; Tellhed L; Xue S; Teraoka S; Bernstein L; Capanu M; Reiner AS; Riedel ER; Thomas DC; Mellemkjaer L; Lynch CF; Boice JD; Anton-Culver H; Bernstein JL
    J Clin Oncol; 2010 May; 28(14):2404-10. PubMed ID: 20368571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
    van den Broek AJ; van 't Veer LJ; Hooning MJ; Cornelissen S; Broeks A; Rutgers EJ; Smit VT; Cornelisse CJ; van Beek M; Janssen-Heijnen ML; Seynaeve C; Westenend PJ; Jobsen JJ; Siesling S; Tollenaar RA; van Leeuwen FE; Schmidt MK
    J Clin Oncol; 2016 Feb; 34(5):409-18. PubMed ID: 26700119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
    Reding KW; Bernstein JL; Langholz BM; Bernstein L; Haile RW; Begg CB; Lynch CF; Concannon P; Borg A; Teraoka SN; Törngren T; Diep A; Xue S; Bertelsen L; Liang X; Reiner AS; Capanu M; Malone KE;
    Breast Cancer Res Treat; 2010 Sep; 123(2):491-8. PubMed ID: 20135344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of multifocal or multicentric disease on local recurrence and survival in breast cancer patients with or without BRCA1/2 variants.
    Liu X; Wang Y; Cao K; Yao L; Hu L; Sun J; Zhang J; Xu Y; Xie Y
    Breast Cancer Res Treat; 2023 May; 199(1):25-33. PubMed ID: 36930346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.